Abstract: Embodiments are directed to compositions and methods for treating viral infections.

Abstract: An adjustable elastic heel strap having first and second elastic closure elements that cooperate to adjustably close the heel. The first elastic closure element is elastic and may be manufactured from a length of elastic webbing. The first elastic closure element may be arranged to engage the wearer's foot. The second elastic closure element is elastic and may be manufactured from an elastic cord. The second elastic closure element may include a cord lock that allows a wearer to selectively vary the effective length and elastic tension of the heel strap. The second elastic closure element may be disposed along the outside of the first elastic closure element to facilitate access. The heel strap may also include a heel pull that is affixed to the first elastic closure element. The heel strap may also include upper and lower retainers that retain and guide the elastic cord and the cord lock.

Abstract: Certain embodiments are directed to compositions and methods for attenuating allergic responses in a subject.

Abstract: Embodiments are directed to methods and compositions for modulating an immune response. In certain aspects the immune response is a type I hypersensitivity response. In particular aspects the subject has allergic asthma or allergic rhinitis. Using a conventional experimental asthma mouse model (BALB/c), the inventors demonstrate that aerosol administration of TLR agonists, in particular a combination of TLR2/6 and TLR9 agonist (e.g., TLR9 oligonucleotide agonist/PAM2CSK4) along with an antigen (e.g., ovalbumin (OVA)) suppresses the immune response as exemplified by the production of antigen-specific IgE and decreases the number of airway eosinophils in bronchoalveolar lavage fluid (BAL) in response to intraperitoneal (IP) immunization with an antigen mixed with alum.

Abstract: Embodiments are directed to compositions and methods for treating viral infections.

Abstract: Embodiments are directed to methods and compositions for modulating an immune response. In certain aspects the immune response is a type I hypersensitivity response. In particular aspects the subject has allergic asthma or allergic rhinitis. Using a conventional experimental asthma mouse model (BALB/c), the inventors demonstrate that aerosol administration of TLR agonists, in particular a combination of TLR2/6 and TLR9 agonist (e.g., TLR9 oligonucleotide agonist/PAM2CSK4) along with an antigen (e.g., ovalbumin (OVA)) suppresses the immune response as exemplified by the production of antigen-specific IgE and decreases the number of airway eosinophils in bronchoalveolar lavage fluid (BAL) in response to intraperitoneal (IP) immunization with an antigen mixed with alum.

Abstract: Embodiments are directed to compositions and methods for treating viral infections.

Abstract: Embodiments are directed to compositions and methods for treating viral infections.